Volume 31, Number 12—December 2025
Research Letter
Metatranscriptomic Identification of Trubanaman Virus Sequences in Patient with Encephalitis, Australia
Table
Results of cerebrospinal fluid testing in an immunocompromised patient with encephalitis in study of metatranscriptomic identification of Trubanaman virus, Australia*
| Test | Result |
|---|---|
| Leukocytes, × 106 cells/L (reference range <5) |
2 |
| Erythrocytes, × 106 cells/L (reference range <5) |
61 |
| Protein, mg/L (reference range 150–500) |
570 |
| Glucose, mmol/L (reference range 2.2–3.9) |
5.3 |
| Microscopy and culture |
No bacteria or fungi detected |
| NAAT for herpes simplex 1 and 2, cytomegalovirus, varicella zoster virus, human herpesvirus 6, John Cunningham virus, enteroviruses, and parechoviruses |
Negative |
| NAAT for Escherichia coli, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, and Cryptococcus spp. |
Negative |
| Cryptococcal antigen in cerebrospinal fluid |
Negative |
| Neuronal antibodies Hu, Ri, Yo, and Purkinje cell cytoplasmic types 2 and Tr |
Negative |
| N-methyl-D-aspartate, GABA-B, and AMPA receptors |
Negative |
| CV2/collapsin response mediator protein 5 |
Negative |
| Ma/Ta, glutamic acid decarboxylase, and amphyphysin antibodies | Negative |
*NAAT, nucleic acid amplification test.
Page created: November 26, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.